Pazopanib (VOTRIENT FCT) Tablet

Name: Pazopanib (VOTRIENT FCT) Tablet
Brand: variable
Availability: InStock

$869.00

VOTRIENT FCT Tablet offers a targeted therapeutic approach for patients with advanced renal cell carcinoma and soft tissue sarcoma, providing a valuable treatment option to help manage these challenging malignancies.

Sku:

N/A

Tag:

Pazopanib

Description

VOTRIENT FCT Tablet contains Pazopanib in strengths of 200mg and 400mg, serving as a targeted therapy medication used primarily in the treatment of certain types of cancer, including advanced renal cell carcinoma (kidney cancer) and advanced soft tissue sarcoma.

Key Features:

Targeted Therapy: VOTRIENT FCT Tablet contains Pazopanib, a tyrosine kinase inhibitor that selectively targets and inhibits multiple receptor tyrosine kinases involved in tumor growth and angiogenesis, thereby slowing cancer progression.
Multiple Strengths: Available in two strengths (200mg and 400mg), facilitating individualized dosing based on factors such as disease stage, patient tolerance, and response to treatment.
Renal Cell Carcinoma Treatment: VOTRIENT FCT is indicated for the first-line treatment of advanced renal cell carcinoma, offering patients a therapeutic option to help manage this aggressive form of kidney cancer.
Soft Tissue Sarcoma Treatment: Additionally, VOTRIENT FCT is approved for the treatment of advanced soft tissue sarcoma in patients who have received prior chemotherapy, providing an alternative treatment option for this rare malignancy.
Oral Administration: Administered orally as a tablet, VOTRIENT FCT offers convenient dosing and improved patient compliance compared to intravenous therapies.
Angiogenesis Inhibition: By inhibiting angiogenesis, the formation of new blood vessels necessary for tumor growth and metastasis is disrupted, leading to tumor shrinkage and potential disease stabilization.
Potential Adverse Effects: Common side effects of VOTRIENT FCT may include fatigue, diarrhea, hypertension, nausea, and hair color changes. Patients should be monitored closely for adverse reactions and managed accordingly.
Individualized Treatment Approach: The selection of the appropriate VOTRIENT FCT dosage and treatment duration should be based on factors such as disease characteristics, patient’s overall health status, and treatment response.